Green Cross said Monday that it has presented non-clinical trial data for MG1121, a hemophilia-A treatment, at the 59th American Society of Hematology. Green Cross is co-developing the drug with Mogam Institute for Biomedical Research (MIBR).
Hemophilia A is a rare genetic disorder, also called factor VIII (FVIII) deficiency or classic hemophilia, which causes hemorrhages. Hemorrhage complications lead to severe edema and pain, arthritis, joint damage, disability, and death.
According to the non-clinical trial results, MG1121 has a half-life of more than three times that of conventional drugs, which is half the blood drug concentration. Such characteristics can improve the convenience of the drug by replacing the dosage of the traditional medicine from once every three days to once a week.
The treatment is also applied to various protein preparation technologies accumulated by Green Cross to increase the half-life and increase the structural stability of drugs, it said.
“Improving the convenience of patients with hemophilia is key to product development,” said Jo Eui-chul, principal investigator at Mogam Institute for Biomedical Research and head of the non-clinical trials. “The company plans to increase the speed of the drug development as it confirmed the decrease in dosage intakes.”
About 80 percent of the 400,000 hemophilia patients in the world are known to be suffering from hemophilia A.
<© Korea Biomedical Review, All rights reserved.>